We have found that inhibiting the H3K9me2 specific methyltransferases, EHMT1 and EHMT2, either with chemical inhibitors or RNAi sensitizes CML cell lines to interferon treatment. This evidence concerns the gene EHMT1 and chronic myelogenous leukemia, BCR-ABL1 positive.